Brief: Harpoon Presents Interim Data From Ongoing Dose Escalation Portion Of T Cell Engager Hpn328 Clinical Trial At 2022 Asco Annual Meeting

Harpoon Therapeutics

27/05/2022 24:41

May 26 (Reuters) - Harpoon Therapeutics Inc  HARP.O :
    * HARPOON PRESENTS INTERIM DATA FROM ONGOING DOSE ESCALATION
PORTION OF T CELL ENGAGER HPN328 CLINICAL TRIAL AT 2022 ASCO
ANNUAL MEETING
    * HARPOON THERAPEUTICS INC - HPN328 CLINICALLY ACTIVE AND
WELL
TOLERATED IN PATIENTS WITH SOLID TUMORS
    * HARPOON THERAPEUTICS -  FAVORABLE SAFETY PROFILE EMERGING:
22%
OF PATIENTS EXPERIENCED GRADE 1-2 CRS; NO GRADE 3 OR HIGHER CRS
FROM HPN328 TRIAL
    * HARPOON THERAPEUTICS - ONE CONFIRMED PARTIAL RESPONSE; 27%
OF
SMALL CELL LUNG CANCER PATIENTS WITH TARGET LESION REDUCTIONS OF
30% OR MORE FROM HPN328 TRIAL
    * HARPOON THERAPEUTICS INC - TREATMENT DURATION NOW GREATER
THAN
20 WEEKS IN ONE-THIRD OF PATIENTS
    * HARPOON THERAPEUTICS INC - DOSE ESCALATION IS ONGOING;
MAXIMUM
TOLERATED DOSE NOT YET REACHED
    * HARPOON THERAPEUTICS - AS OF DATA CUT-OFF DATE OF APRIL
21,
2022, SHOWED THAT HPN328 DEMONSTRATED ANTI-TUMOR ACTIVITY AND A
FAVORABLE SAFETY PROFILE
    * HARPOON THERAPEUTICS INC - TO DATE, THERE HAVE BEEN NO
DOSE-LIMITING TOXICITIES OBSERVED AND NO DISCONTINUATIONS DUE TO
ADVERSE EVENTS

Source text for Eikon:  ID:nGNX8V6lHK 
Further company coverage:  HARP.O 

 ((Reuters.Briefs@thomsonreuters.com;))